Benzimidazole‐oxindole hybrids: A novel class of selective dual CDK2 and GSK‐3β inhibitors of potent anticancer activity

Abstract

AbstractA new series of benzimidazole‐oxindole hybrids 8a–x was discovered as dual cyclin‐dependent kinase (CDK2) and glycogen synthase kinase‐3‐beta (GSK‐3β) inhibitors with potent anticancer activity. The synthesized hits displayed potent anticancer activity against national cancer institute cancer cell lines in single‐dose and five‐dose assays. Moreover, the derivatives 8k, 8l, 8n, 8o, and 8p demonstrated potent cytotoxic activity against PANC‐1 cells with IC50 = 1.88–2.79 µM. In addition, the hybrids 8l, 8n, 8o, and 8p displayed potent antiproliferative activity on the MG‐63 cell line (IC50 = 0.99–1.90 µM). Concurrently, the benzimidazole‐oxindole hybrid 8v exhibited potent dual CDK2/GSK‐3β inhibitory activity with IC50 values of 0.04 and 0.021 µM, respectively. In addition, 8v displayed more than 10‐fold higher selectivity toward CDK2 and GSK‐3 β over CDK1, CDK5, GSK‐3α, vascular endothelial growth factor receptor‐2, and B‐rapidly accelerated fibrosarcoma. Screening of the effect of 8n and 8v on the cell cycle and apoptosis of PANC‐1 and MG‐63 cells displayed their ability to arrest their cell cycle at the G2‐M phase and to potentiate the apoptosis of both cell lines. In silico docking of the benzimidazole‐oxindole hybrid 8v into the catalytic pocket of both CDK2 and GSK‐3β revealed its perfect fitting through the formation of hydrogen bonding and hydrophobic interactions with the key amino acids in the binding sites. In addition, in silico absorption, distribution, metabolism, excretion studies proved that 8a–x exhibit satisfactory drug‐likeness properties for drug development.